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ORIGINAL ARTICLE
The relationship between maternal plasma homocysteine in early pregnancy
and birth weight
Shona Cawleya,b, Eimer G. O’Malleya , Rachel A. K. Kennedya,b, Ciara M. E. Reynoldsa, Anne M. Molloyc
and Michael J. Turnera
aUCD Centre for Human Reproduction, Coombe Women and Infants, University Hospital, Dublin, Ireland; bSchool of Biological
Sciences, Dublin Institute of Technology, Dublin, Ireland; cSchool of Medicine, Trinity College Dublin, Dublin, Ireland
ABSTRACT
Background: There is limited evidence that plasma homocysteine (Hcy) is increased in women
with adverse pregnancy outcomes, such as low birth weight (LBW).
Objective: We examined the relationship between maternal Hcy at the first prenatal visit and
birth weight.
Study design: In a prospective observational study, women were recruited during their first pre-
natal visit after sonographic confirmation of gestational age. Along with the standard tests,
blood was also taken for the measurement of maternal serum and red blood cell (RBC) folate,
vitamin B12, and Hcy. In addition to collecting standard clinical and sociodemographic details, a
detailed questionnaire on vitamin supplementation was completed under supervision. Birth out-
comes were collected immediately after delivery.
Results: Of 498 women recruited, 213 (42.8%) were nulliparous, 97 (19.4%) were obese, 64
(12.9%) selfreported as current smokers, and 489 (98.2%) were taking folic acid (FA) supplements
at presentation. The mean (SD) birth weight was 3426.3 g (600.7), 14.0% of infants were small
for gestational age, and 7.4% were large for gestational age. Mean (SD) plasma Hcy was 7.1
(2.1) mmol/l. On multiple linear regression, higher plasma Hcy was associated with selfreported
smoking (p¼ .009), relative income poverty (p¼ .037) and Irish nativity (p¼ .009). There was no
relationship between maternal plasma Hcy and birth weight centile, either overall or when ana-
lyzed separately for either smokers (r¼ 0.0001, p¼ .98) and nonsmokers (r¼0.007, p¼ .097).
Plasma Hcy was correlated negatively with serum folate, RBC folate, and serum vitamin B12.
There was no association between maternal Hcy and the duration of FA supplementation in
weeks (r¼0.08, p¼ .083) or between maternal Hcy and gestational age at phlebotomy
(r¼0.54, p¼ .35).
Conclusions: In this well-characterized cohort of women in early pregnancy, there was no cor-
relation between maternal plasma Hcy and birth weight. However, higher Hcy was associated
with maternal smoking and social deprivation which may explain the association reported previ-
ously between an increased Hcy and LBW.
Rationale
This study was conducted to investigate the relationship between maternal homocysteine in
early pregnancy and infant birth weight. Increased plasma homocysteine in early pregnancy was
not associated with a lower birth weight. However, there was a positive correlation between
increasing plasma homocysteine and maternal smoking and social disadvantage which are risk
factors for lower birth weight. This study highlights the importance of correcting for confound-
ing variables, such as smoking and social disadvantage, when evaluating the relationship mater-
nal nutritional biomarkers and intrauterine fetal development.
RATIONALE
This study was conducted to investigate the relationship between maternal homocysteine in
early pregnancy and infant birth weight. Increased plasma homocysteine in early pregnancy was
not associated with a lower birth weight. However, there was a positive correlation between
increasing plasma homocysteine and maternal smoking and social disadvantage which are risk
factors for lower birth weight. This study highlights the importance of correcting for confound-
ing variables, such as smoking and social disadvantage, when evaluating the relationship mater-
nal nutritional biomarkers and intrauterine fetal development.
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Introduction
Homocysteine (Hcy) is a sulfur-containing amino acid
that is a demethylated derivative of methionine and
which is not used in protein synthesis [1]. It is metabo-
lized by two main pathways: remethylation to methio-
nine or, transsulphuration to cystathionine and then
to cysteine [2]. The conversion of Hcy to methionine is
the only human reaction that requires both folate and
vitamin B12 as cofactors. A defect in either of the
main pathways leads to an accumulation of Hcy. The
defect may be congenital or due to deficiencies in
micronutrients. Deficiencies in folate or vitamin B12
compromise the remethylation pathway. Deficiencies
in vitamin B6 compromise the transsulphuration path-
way [3].
Plasma Hcy is 30–60% lower in pregnancy [1,4,5].
This may be explained by the many physiological
changes in pregnancy including the haemodilutional
changes in albumin levels as 70–80% of Hcy is bound
to albumin. Several longitudinal studies found that
total Hcy levels were lower in the second trimester
but increased in the third trimester [4,5].
Interpretation of maternal plasma Hcy levels, therefore,
depend on the timing of sampling in relationship to
gestational age.
Plasma Hcy levels are correlated negatively with
plasma vitamin B12, plasma folate, and folate during
pregnancy [4]. Hcy levels are decreased in women tak-
ing Folic acid (FA) supplementation and are increased
in women with pregnancies complicated by neural
tube defects (NTDs) compared with controls [6,7]. In a
meta-analysis involving mothers of 1304 NTD cases in
17 studies between 1966 and 2015, the increase in
Hcy was associated with an increased risk of NTDs;
however, this was not significant in the four countries
where folate fortification was mandatory [7]. It should
be noted that 11 of the 17 studies in the meta-ana-
lysis measured Hcy after delivery. None of the studies
reported on measurements from pregnancies in the
first trimester [7]. An increased Hcy level has also been
associated with intrauterine fetal growth restriction [5].
Previous studies have demonstrated an association
between increasing Hcy and low birth weight. A study of
100 women measured serum Hcy at 8–12-week gestation
and reported an association between higher Hcy in the
first trimester and delivery of a low birth weight baby
(birth weight  2500g; mean Hcy 12.35±5.64mmol/L
and birth weight < 2500g; mean Hcy
23.22±12.32mmol/L, p¼ .0224) [8]. There was no correc-
tion for any potential confounding factors reported.
A study of 700 women in India measured vitamin
B12, Hcy, and folate at 18 and 28weeks gestation [9].
Almost one-third (28%) of the study population had a
Hcy level > 10mmol/L at 18weeks while 60% were
deficient in vitamin B12 and just one had a red blood
cell (RBC) folate level considered deficient. They found
an association between increased Hcy at 18-week ges-
tation and a smaller newborn size based on the meas-
urement of anthropometric measurements of
midupper arm circumference (p¼ .02), abdominal cir-
cumference (p¼ .02), and subscapular and triceps skin-
fold thickness (p¼ .001 and p¼ .007 respectively). This
study does not report the association with the fetal
weight or comment on the incidence of smoking. The
aim of this prospective observational study was to
examine the relationship between maternal Hcy levels
in early pregnancy and birth weight.
Materials and methods
The hospital is one of the largest maternity hospitals
in Europe and cares for women from all socioeco-
nomic groups across the urban–rural divide. Women
were recruited at their convenience during their first
prenatal visit between June 2014 and March 2016
after sonographic confirmation of an ongoing single-
ton pregnancy. Exclusion criteria were maternal age <
18 years, multiple pregnancies, a history of a previous
NTD, or an inability to understand English. Informed
written consent was obtained. Women’s clinical and
sociodemographic details were computerized routinely
and updated immediately after delivery. The Gestation
Related Optimal Weight (GROW) bulk centile calculator
v8.0.1 was used to convert birth weight (BW) to birth
weight centiles [10]. The calculator adjusted birth
weight for the following confounding variables: mater-
nal ethnicity, maternal height and weight, parity,
infant gender, gestation at birth, and birth weight.
Small for gestational age (SGA) is defined as a birth
weight centile  10th centile, large for gestational age
(LGA) as a birth weight centile  90th centile, and
appropriate for gestational age (AGA) if a BW centile is
between the 10th and 90th centile.
At the time of taking the routine first visit blood
tests, additional samples were taken for serum and
RBC folate, serum vitamin B12, and plasma Hcy meas-
urements. These samples were transported in a cool
box within 4 hours of extraction for separation, storage
at 70 C, and analysis. Plasma Hcy was measured
using a Roche Cobas 8000 (c502) analyzer using Axis-
Shield liquid stable 2-part homocysteine reagent.
Serum and RBC folates were performed by a microbio-
logical method, using a microtitre plate adaptation of
the chloramphenicol-resistant Lactobacillus casei
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method [11]. Serum vitamin B12 was measured using
a microtitre plate adaptation of the colistin-resistant
microorganism Lactobacillus leichmannii after carrying
out an initial extraction step [12]. A detailed question-
naire about all nutritional supplement intakes was
completed under the supervision of a research diet-
itian (SC). To collect estimated habitual food intakes
for the analysis of total dietary folate (natural folate
and synthetic FA from fortified foods), women were
asked to complete a retrospective 4-day Diet History
(DH) under supervision. This was combined with a cus-
tomized Food Frequency Questionnaire (FFQ) to cap-
ture the brand names of foods fortified with FA. This
is because in Ireland FA is added to food on a volun-
tary basis and the amount added varies according to
the brand. Information on socioeconomic status was
assessed using questions from the European Union
Survey on Income and Living Conditions [13].
Data from the participants’ questionnaires were
anonymized and coded on a Microsoft ExcelVR spread-
sheet and statistical analysis was conducted using
SPSS for Windows, version 20 (IBM Corporation,
Armonk, NY, USA). The distribution of data for con-
tinuous variables was assessed for normality.
Descriptive statistics were first used to characterize the
study cohort. One-way ANOVA and independent-sam-
ples t-tests were used to compare mean Hcy levels
with the time of initiation of FA supplementation in
weeks. Pearson and Spearman’s correlations were
used to assess the correlation between Hcy and folate
biomarkers, vitamin B12, and birth weight centile
(depending on whether the variable was normally dis-
tributed or not). A one-way ANOVA with a Tukey post
hoc test was used to investigate the association
between maternal Hcy and birth weight centile groups
(SGA, normal, or LGA). Multivariable regression analysis
was used to assess the association between plasma
Hcy and demographic factors. This study was
approved by the Hospital’s Research Ethics Committee
in 2013 (Study number 27–2013).
Results
The characteristics of the study population are shown
in Table 1 and they are similar to those reported in
the Annual Hospital Clinical Report [14]. The relation-
ship between plasma mean (SD) Hcy and maternal
variables is shown in Table 2.
On multiple regression analysis, after controlling for
those factors which were significant predictors of Hcy
levels on univariate analysis (pregnancy intention,
marital status, smoking status, relative income poverty,
age, preconceptional FA use, FA during pregnancy,
country of birth and third level education), only smok-
ing (b¼ 0.169, p¼ .009), relative income poverty
(b¼ 0.129, p¼ .037), and Irish nativity (b¼ 0.144,
p¼ .009), remained predictive of having a higher
Hcy level.
Table 1. Characteristics of the study population (n¼ 498).
Age < 30 years (%, n) 39.0 (194)
Nulliparas (%, n) 42.8 (213)
Obese (%, n) 19.4 (97)
Planned Pregnancy (%, n) 62.7 (312)
Current Smoker (%, n) 12.9 (64)
Born in Ireland (%, n) 74.7 (371)
Table 2. Mean (SD) total maternal homocysteine (mmols/l)
analyzed according to maternal characteristics.
Homocysteine (mmols/l) p
Planned pregnancy
Yes (n¼ 312) 6.9 (1.9) <.001
No (n¼ 186) 7.5 (2.5)
Parity
Nulliparous (n¼ 213) 7.1 (1.7) .91
Multiparous (n¼ 285) 7.1 (2.4)
Married
Yes (n¼ 246) 6.7 (1.6) <.001
No (n¼ 252) 7.5 (2.5)
Smoking
Current (n¼ 64) 8.3 (3.3) <.001
Nonsmoker (n¼ 434) 6.9 (1.9)
Consistent Poverty
Yes (n¼ 13) 8.7 (4.0) .16
No (n¼ 291) 7.0 (2.1)
Deprivation
Yes (n¼ 37) 8.0 (3.4) .32
No (n¼ 412) 6.8 (1.6)
Relative income poverty
Yes (n¼ 74) 8.0 (3.4) .007
No (n¼ 231) 6.8 (1.6)
Obesity
Obese (n¼ 97) 7.2 (2.4) .67
Nonobese (n¼ 401) 7.1 (2.1)
Maternal Age (years)
<30 (n¼ 194) 7.6 (2.7) <.001
30 (n¼ 304) 6.8 (1.6)
Preconceptional FA
Yes (n¼ 213) 6.8 (2.0) <.001
No (n¼ 285) 7.4 (2.2)
County of residence
Dublin (n¼ 317) 7.2 (2.2) .5
Outside Dublin (n¼ 181) 7.0 (2.1)
Third Level Education
Yes (n¼ 270) 6.8 (1.8) .01
No (n¼ 178) 7.4 (2.4)
Country of birth 7.4 (2.3)
Ireland (n¼ 371) 6.6 (1.4) Reference CategoryEU 14 (n ¼ 32) 6.7 (1.5) .15EU 13 (n¼ 54) 5.9 (1.1) .10
Other (n¼ 41) <.001
Folic Acid in pregnancy
Yes (n¼ 484) 7.1 (2.1) <.001
No (n¼ 9) 10.2 (4.0)
SD: standard deviation.EU 14 (Austria, Belgium, Finland, France, Germany, Greece, Italy,
Luxembourg, Netherland, Portugal, Spain, Sweden, UK).EU13 (Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta,
Poland, Slovenia, Slovakia, Romania, Bulgaria, Croatia).
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There was no difference between Hcy levels and
BW centile grouping (comparing SGA and AGA
p¼ .092, SGA and LGA p¼ 0.058 and AGA and LGA
p¼ .498). This was true whether the woman reported
smoking or not. There was no relationship between
birth weight centile and Hcy for either smokers
(r¼ 0.0001, p¼ .98) or nonsmokers (r¼0.007,
p¼ .097). There was also no association between RBC
folate, plasma folate and plasma vitamin B12 and
infant birth weight centile (RBC folate and BW centile
 r¼0.033, p¼ 0.482, plasma folate and BW centile
 q¼ 0.051, p¼ .274 and plasma vitamin B12 and BW
centile  q¼ 0.078, p¼ .090).
There was a negative association between maternal
Hcy and serum folate (r¼0.285, p< .001) and RBC
folate (r¼0.353, p< .001), and between maternal
Hcy and vitamin B12 measurements (r¼0.260,
p< .001). There was no association between maternal
Hcy and maternal total dietary folate (r¼0.062,
p¼ .32) or dietary vitamin B12 (r¼0.084, p¼ .18)
(See supplementary data). There was also no associ-
ation between maternal Hcy and the duration of FA
supplementation in weeks (r¼0.08, p¼ .083) (see
Supplementary Table 1) or between maternal Hcy and
gestational age at phlebotomy (r¼0.54, p¼ .35).
Within the population studied, there was excellent
compliance with folic acid supplementation at the time
of the first prenatal visit (98.2%) with just 3.6% (n¼ 18)
of women with a plasma folate level below that consid-
ered as deficient (<10nmol/L) and 1.0% (n¼ 5) defi-
cient based on RBC folate (<340nmol/l). There was a
higher rate of vitamin B12 deficiency within the cohort
with 19.5% (n¼ 98) of women studied with a plasma
vitamin B12 level below 150pmol/L.
Discussion
In this prospective observational study of women in
early pregnancy, we found that maternal Hcy levels
did not correlate negatively with birth weight centiles.
On linear regression analysis, Hcy did correlate nega-
tively with selfreported smoking, relative income pov-
erty, and Irish nativity.
Our study has strengths. Detailed clinical, sociode-
mographic, dietary intakes, and vitamin supplementa-
tion details were collected under the supervision of a
single researcher in the same cohort of participants in
early pregnancy. Phlebotomy was performed at the
same visit to measure Hcy and other associated nutri-
tional biomarkers vitamin B12 and folate. A limitation
is that information on maternal smoking was selfre-
ported and not verified by biochemical testing. It is
also notable that this study was undertaken in a coun-
try where folate food fortification is voluntary and not
mandatory. Compliance with FA supplementation at
the time of recruitment was high.
In a Spanish study of 93 pregnant women aged
18–35 years, the neonates of mothers in the highest
tertile of plasma Hcy measured before pregnancy, at
8-week gestation, and again in labor, weighed less
than neonates born to mothers in the low-medium
tertiles [5]. All the pregnancies were planned, but the
women did not take FA in the first trimester.
In an Australian study of 137 women at 18–20-
week gestation, women with intrauterine growth
restriction (IUGR) had an increased plasma Hcy con-
centration compared with controls (p< .001) [13].
Those who had a pregnancy complicated by IUGR
were more likely to smoke than controls (p< .004).
Women who smoked during pregnancy, however, had
an average plasma Hcy level that was 27% higher
than nonsmokers.
In a systematic review and meta-analysis of mater-
nal Hcy and SGA offspring, 19 studies were identified
with 21,326 participants [15]. Higher maternal Hcy
concentrations were associated with a small increased
risk of SGA. The study estimated that birth weight
decreased 31 g for every 1 SD increase in maternal
Hcy. The clinical relevance of this decrease was uncer-
tain. Of the eight studies that used regression analysis,
only two adjusted for smoking and both of these
studies measured maternal Hcy in the third trimester.
Previous reports have also associated an increased
Hcy with different obstetric complications including
abruptio placentae, preeclampsia, stillbirth, and recur-
rent miscarriage as well as NTDs [6,16]. This has led to
the suggestion that FA supplementation could poten-
tially reduce the risk of obstetric complications related
to high levels of maternal Hcy [5]. Due to the inverse
relationship between folate and vitamin B12 levels and
Hcy, it is important that the status of these biomarkers
is investigated in parallel with Hcy. We have previously
demonstrated that obese women in this cohort were
found to have lower levels of plasma folate and plasma
vitamin B12 compared to women with a normal BMI
(q¼0.100, p¼ .300 and q¼0.100, p¼ .026) [17].
Other studies have also shown that a higher folate level
can be protective against the effect of genetic variation
in the MTHFR enzyme that results in reduced efficiency
in the breakdown of Hcy to methionine [18]. Our find-
ings suggest that any epidemiological associations
between increased maternal Hcy and adverse preg-
nancy outcomes may be influenced by other factors
such as smoking or social disadvantage.
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In conclusion, the absence of an association
between maternal plasma Hcy and birth weight in this
well-characterized population following multiple linear
regression analysis means that future studies that
examine the relationship between intrauterine fetal
growth and maternal nutrient measurements in preg-
nancy need to correct for confounding variables which
influence fetal growth, particularly maternal smoking.
Acknowledgements
We thank the women who participated and our laboratory
and midwifery colleagues, particularly Ruth Harley and
Muireann Nı Mhurchu from the Hospital’s Biobank, for their
assistance. We thank the all-island body Safefood for fund-
ing this research.
Disclosure statement
No potential conflict of interest was reported by the authors.
Funding
This work was supported by Safefood, an all-island body
funded under the Good Friday Agreement, grant number
[02–2015]. The researchers are independent from funders.
ORCID
Eimer G. O’Malley http://orcid.org/0000-0002-8100-4761
References
[1] Ubeda N, Reyes L, Gonzalez-Medina A. Physiologic
changes in homocysteine metabolism in pregnancy: a
longitudinal study in Spain. Nutrition. 2011;27:
925–930.
[2] Megahed MA, Taher IM. Folate and homocysteine lev-
els in pregnancy. Br J Biomed Sci. 2004;61:84–87.
[3] Bjørke Monsen ALB, Ueland PM. Homocysteine and
methylmalonic acid in diagnosis and risk assessment
from infancy to adolescence. Am J Clin Nutr. 2003;78:
7–21.
[4] Walker MC, Smith GN, Perkins SL, et al. Changes in
homocysteine levels during normal pregnancy. Am J
Obstet Gynecol. 1999;180:660–664.
[5] Murphy MM, Scott JM, Arija V, et al. Maternal homo-
cysteine before conception and throughout preg-
nancy predicts fetal homocysteine and birth weight.
Clin Chem. 2004;50:1406–1412.
[6] Mills JL, McPartlin JM, Kirke PN, et al. Homocysteine
metabolism in pregnancies complicated by neural-
tube defects. Lancet. 1995;345:149–151.
[7] Yang M, Li W, Wan Z, et al. Elevated homocysteine
levels in mothers with neural tube defects: a system-
atic review and meta-analysis. J Matern Fetal
Neonatal Med. 2016;3:1–7.
[8] Mascarenhas M, Habeebullah S, Sridhar MG. Revisiting
the role of first trimester homocysteine as an index of
maternal and fetal outcome. J Pregnancy. 2014;2014:1.
[9] Yajnik CS, Deshpande SS, Jackson AA, et al. Vitamin
B12 and folate concentrations during pregnancy and
insulin resistance in the offspring: the Pune Maternal
Nutrition Study. Diabetologia. 2007;51:29–38.
[10] Gardosi J, Francis A, Turner S, et al. Customized
growth charts: rationale, validation and clinical bene-
fits. Am J Obstet Gynecol. 2018;218:S609–S618.
[11] Molloy AM, Scott JM. Microbiological assay for serum,
plasma, and red cell folate using cryopreserved,
microtiter plate method. Methods Enzymol. 1997;281:
43–53.
[12] Kelleher BP, Broin SD. Microbiological assay for vita-
min B12 performed in 96-well microtitre plates. J Clin
Pathol. 1991;44:592–595.
[13] Central Statistics Office. European Union (EU) survey
on Income and Living Conditions (EU-SILC) 2011 and
Revised 2010 Results. Dublin (Ireland): Central
Statistics Office; 2013.
[14] Coombe Women and Infants University Hospital
annual clinical Report 2014; [cited 2018 Jan 14].
Available from: http://www.coombe.ie/index.
php?nodeId¼110
[15] Furness D, Fenech M, Dekker G, et al. Folate,
vitamin B12, vitamin B6 and homocysteine: impact on
pregnancy outcome. Matern Child Nutr. 2013;9:
155–166.
[16] Hogeveen M, Blom HJ, den Heijer M. Maternal homo-
cysteine and small-for-gestational-age offspring: sys-
tematic review and meta-analysis. Am J Clin Nutr.
2012;95:130–136.
[17] O’Malley EG, Reynolds CME, Cawley S, et al. Folate
and vitamin B12 levels in early pregnancy and mater-
nal obesity. Eur J Obstet Gynecol Reprod Biol. 2018;
231:80–84.
[18] Relton CL, Pearce MS, Burn J, et al. An investigation
of folate-related genetic factors in the determination
of birthweight. Paediatr Perinat Epidemiol. 2005;19:
360–367.
THE JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE 3049
